Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$87.37

-1.85 (-2.07%)

, CELG

Celgene

$142.04

1.43 (1.02%)

04:55
09/17/17
09/17
04:55
09/17/17
04:55

European Academy of Dermatology & Venereology to hold a conference

26th EADV Congress is being held in Geneva, Switzerland on September 13-17.

ABBV

AbbVie

$87.37

-1.85 (-2.07%)

CELG

Celgene

$142.04

1.43 (1.02%)

CUTR

Cutera

$38.55

1.1 (2.94%)

DERM

Dermira

$26.29

-0.24 (-0.90%)

GSK

GlaxoSmithKline

$40.24

-0.11 (-0.27%)

JNJ

Johnson & Johnson

$134.45

0.27 (0.20%)

LLY

Eli Lilly

$82.44

-0.63 (-0.76%)

LMNS

Lumenis

NVS

Novartis

$85.58

-0.25 (-0.29%)

PFE

Pfizer

$35.36

-0.37 (-1.04%)

SNY

Sanofi

$48.43

-0.29 (-0.60%)

REGN

Regeneron

$433.45

-7.81 (-1.77%)

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 28

    Sep

  • 17

    Oct

  • 18

    Oct

  • 24

    Oct

  • 17

    May

ABBV AbbVie
$87.37

-1.85 (-2.07%)

09/11/17
COWN
09/11/17
NO CHANGE
Target $95
COWN
Market Perform
AbbVie price target raised to $95 from $70 at Cowen
Cowen analyst Steve Scala raised his price target on Abbvie to $95 from $70 to reflect his raised estimates to account for higher Humira forecasts. The company received an important victory regarding an IPR targeting a Humira formulation, which he feels will allow Abbvie to hold Humira sales at least flat during 2020-2022. This has big bottom line implications, said Scala, who maintained his Market Perform rating on Abbvie shares.
09/13/17
RHCO
09/13/17
NO CHANGE
RHCO
AbbVie data increases confidence in RA opportunity, says SunTrust
SunTrust analyst John Boris says that data on AbbVie's (ABBV) UPAD for rheumatoid arthritis shows that its efficacy "appears competitive" with that of Pfizer's (PFE) Xeljanz/XR. The analyst says that the data increases his confidence in AbbVie's opportunity in RA. He keeps a $95 price target and a Buy rating on the shares.
09/15/17
PIPR
09/15/17
NO CHANGE
Target $100
PIPR
Overweight
AbbVie price target raised to $100 from $85 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss raised his price target for AbbVie (ABBV) to $100 after pushing out a U.S. biosimilar entry for Humira by two years. The recent denials by the Patent Trial and Appeal Board of all four of Coherus Bioscience's (CHRS) inter partes review petitions reinforce the patentability of Humira's formulation, Purkiss tells investors in a research note. The analyst pushed out his view of the likely timing of the first U.S. biosimilar launch versus Humira to the second half of 2022 from the second half of 2020. He estimates Humira will still account for 58% of AbbVie's total revenue in 2020. The analyst reiterates an Overweight rating on the shares.
09/15/17
JEFF
09/15/17
NO CHANGE
Target $107
JEFF
Buy
AbbVie price target raised to $107 from $94 at Jefferies
Jefferies analyst Jeffrey Holford raised his price target for AbbVie (ABBV) to $107 after Coherus Biosciences (COHR) failed to gain institution of an inter partes review on a key formulation Humira patent. The analyst says his two-stage thesis on AbbVie has been that consensus expectations for U.S. Humira biosimilars would be pushed back, allowing investors to "finally focus" on the value inside the rest of the company and the pipeline. In a research note titled "Stage I Complete; More Upside on Offer from Stage II," Holdford reiterates AbbVie as his Top Pick with a Buy rating.
CELG Celgene
$142.04

1.43 (1.02%)

09/14/17
RBCM
09/14/17
INITIATION
Target $176
RBCM
Top Pick
Celgene initiated with a Top Pick at RBC Capital
RBC Capital analyst Brian Abrahams started Celgene with a Top Pick rating and $176 price target. The company's "best-in-class medium-term growth prospects are substantially undervalued relative to peers," the analyst tells investors in a research note.
09/11/17
MAXM
09/11/17
NO CHANGE
MAXM
BeiGene data, Celgene deal closing positive, says Maxim
Maxim analyst Gabrielle Zhou says that preliminary data on a Phase 1/II trial of BeiGene's (BGNE) BGB-290 in patients with advanced solid tumors, including epithelial ovarian cancer, or EOC, showed that the drug has "a similar, if not superior anti-tumor effect compared to other PARP inhibitors in patients with EOC and other solid tumors." Zhou adds that the closing of the company's deal with Celgene (CELG) is also positive. The analyst raised her price target on BeiGene to $77 from $73 and keeps a Buy rating on the stock.
09/08/17
FBCO
09/08/17
NO CHANGE
Target $156
FBCO
Outperform
Celgene trial holds more class-wide than durvalumab-specific, says Credit Suisse
Credit Suisse analyst Alethia Young does not think the clinical holds placed by the FDA on Celgene's (CELG) PD1 trials for durvalumab have anything to do with the safety issue of the trials, but are more of a class-wide review taken after the hold on Merck's (MRK) Keytruda, she tells investors in a research note. Celgene said it has not seen a risk/benefit imbalance in the over 500 patients treated in the FUSION program, she added. Young, who currently doesn't include durvalumab in her valuation of Celgene, keeps an Outperform rating and $156 price target on the stock.
09/08/17
ADAM
09/08/17
NO CHANGE
Target $156
ADAM
Buy
FDA FUSION program hold of minimal concern for Celgene, says Canaccord
Canaccord analyst John Newman noted the FDA put a partial hold on five trials and a full hold on one trial in the FUSION program, but said it should have minimal impact on Celgene fundamentals. The analyst still sees year-end approval for ozanimod and continued Revlimed revenue growth to support its valuation. Newman maintained his Buy rating and $156 price target on Celgene shares.
CUTR Cutera
$38.55

1.1 (2.94%)

09/14/17
09/14/17
DOWNGRADE

Hold
Follow-up: Cutera downgraded to Hold from Buy at Maxim
As previously reported, Maxim downgraded Cutera to Hold from Buy with a $33 price target. Analyst Anthony Vendetti changed is view citing valuation and difficult year--over-year comps ahead.
09/12/17
ROTH
09/12/17
NO CHANGE
Target $47
ROTH
Buy
Cutera price target raised to $47 from $41 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for Cutera to $47 from $41 after meeting with management. The analyst came away with a bullish view on the company's "meaningful" future growth opportunity with truSculpt in the large and high-growth body contouring market, an aspect which he believes remains underappreciated. Lewis reiterates a Buy rating on the shares.
08/08/17
ROTH
08/08/17
NO CHANGE
Target $39
ROTH
Buy
Cutera price target raised to $39 from $32 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for Cutera to $39 from $32 after the company reported a "robust" Q2 beat and raised its full-year revenue and EPS outlook. The analyst reiterates a Buy rating on the shares.
06/27/17
GABE
06/27/17
NO CHANGE
GABE
Buy
Cutera named a 2H 2017 best idea at Gabelli
Gabelli analyst Jennie Tsai named Cutera saying new leadership in various regions along with a renewed focus to drive sustainable growth make it a second half 2017 best idea. The analyst expects increased revenue through sales force expansion and new products and said recent M&A among laser dermatology companies will provide opportunities to drive sustainable growth and market share. Cutera is Buy rated with a $33 price target.
DERM Dermira
$26.29

-0.24 (-0.90%)

06/22/17
CANT
06/22/17
INITIATION
CANT
Overweight
Dermira initiated with an Overweight at Cantor
Cantor analyst Louise Chen started coverage of Dermira with a $45 price target and a buy rating. The analyst expects the FDA to approve the company's DRM04 drug for excessive sweating in 2018, and she thinks that the company's Cimzia drug for psoriasis could gain more market share than expected.
06/29/17
EVER
06/29/17
INITIATION
Target $48
EVER
Outperform
Dermira initiated with an Outperform at Evercore ISI
Evercore analyst Umer Raffat initiated Dermira with an Outperform rating and a $48 price target.
06/30/17
06/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rite Aid (RAD) reinstated with an Underperform at Evercore ISI. 2. Hill-Rom (HRC) initiated with a Buy at Needham and Neutral at Cantor. 3. Dermira (DERM) initiated with an Outperform at Evercore ISI. 4. Coach (COH) initiated with a Buy at Canaccord. 5. WWE (WWE) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/17
CANT
09/08/17
NO CHANGE
Target $45
CANT
Overweight
Things keep getting better for Dermira, says Cantor
In a research note titled "Things Just Keep Getting Better Ahead of Stock Moving Catalysts In 2018," Cantor Fitzgerald analyst Louise Chen says she sees three things that may be driving Dermira (DERM) shares higher. New data which support and improve the commercial opportunity for Cimzia and DRM04, positive Phase 2b data from AbbVie's (ABBV) atopic dermatitis drug, which could help expand the market and the opportunity for Dermira's Lebrikizumab, and positive meetings with investors at a healthcare conference yesterday, Chen tells investors. The analyst keeps an Overweight rating on the shares with a $45 price target.
GSK GlaxoSmithKline
$40.24

-0.11 (-0.27%)

09/08/17
MSCO
09/08/17
DOWNGRADE
MSCO
Underweight
GlaxoSmithKline downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier downgraded GlaxoSmithKline to Underweight saying its 2020 roadmap appears "challenging" given capital allocation constraints and low R&D optionality.
08/30/17
ARGS
08/30/17
NO CHANGE
ARGS
GlaxoSmithKline weakness creates buying opportunity, says Argus
Argus analyst John Eade says that the 8% decline in GlaxoSmithKline's stock over the past quarter has created a buying opportunity. The analyst expects the company's profits to rise by low single percentage digits in 2017 and 2018, and he calls its 5% dividend yield attractive.
07/10/17
PIPR
07/10/17
NO CHANGE
Target $5
PIPR
Neutral
OncoMed termination from GSK not surprising, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes GlaxoSmithKline (GSK) terminating its agreement with OncoMed Pharmaceuticals (OMED) is not surprising since tarextumab, the only remaining asset under the collaboration, failed previously to meet the primary endpoint in a Phase II study for first-line small cell lung cancer. The analyst says he remains focused on OncoMed's early stage pipeline including navicixizumab, rosmantuzumab and I/O assets anti-TIGIT and GITR trimer. Tenthoff keeps a Neutral rating on OncoMed with a $5 price target.
07/05/17
07/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Capital One (COF) downgraded to Underperform from Neutral at Wedbush with analyst Henry Coffey saying ROE from operations is much lower than expected, and return on capital measures are sub-optimal. 2. Weyerhaeuser (WY) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos saying his thesis has played out and catalysts are limited in the intermediate term. 3. Buffalo Wild Wings (BWLD) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh saying the proxy fight and management shake-up has created uncertainty regarding the company's future and said a downward revision to guidance is likely due to continued margin pressures, soft topline trends, and lack of near-term catalysts. 4. GlaxoSmithKline (GSK) downgraded to Neutral from Buy at Citi with analyst Andrew Baum saying he believes the market is under-appreciating the slowing of the company's HIV market growth. 5. Oneok (OKE) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Tom Abrams saying risk/reward is balanced. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JNJ Johnson & Johnson
$134.45

0.27 (0.20%)

08/02/17
PIPR
08/02/17
NO CHANGE
Target $7
PIPR
Overweight
Imbruvica approval in graft versus host positive for Kadmon, says Piper Jaffray
After the FDA expanded the approval of AbbVie (ABBV) and Johnson & Johnson's (JNJ) Imbruvica for the treatment of adults with chronic graft versus host disease, or cGVHD, Piper Jaffray analyst Edward Tenthoff said he views the news as positive for Kadmon's KD025. Imbruvica is tough for patients to tolerate, said Tenthoff, who sees an opportunity for KD025 to more safely treat cGVHD patients. He keeps an Overweight rating and $7 price target on Kadmon shares.
08/14/17
BTIG
08/14/17
UPGRADE
Target $100
BTIG
Buy
Masimo upgraded to Buy, could be acquired by Johnson & Johnson, says BTIG
BTIG analyst Sean Lavin upgraded Masimo (MASI) to Buy from Neutral with a $100 price target saying he is more bullish on the Philips (PHG) agreement leading to increased revenue and margins, and the recent share pullback has provided a buying opportunity. Lavin said Masimo has been executing "superbly" and believes the Philips' relationship will drive acceptance of hemoglobin and Rainbow. Further, the analyst thinks Johnson & Johnson (JNJ) could be an acquirer of Masimo as it sells its products into the OR and ICU markets and would "massively" expand operating margins, and notes Philips may see the value of Masimo's products and make a bid.
08/16/17
JPMS
08/16/17
NO CHANGE
Target $148
JPMS
Overweight
Johnson & Johnson price target raised ahead of ESC meeting at JPMorgan
JPMorgan analyst Michael Weinstein raised his price target for Johnson & Johnson shares to $148 from $140 ahead of the European Society of Cardiology beginning on August 26. The big event for J&J is the presentation of the COMPASS trial, investigating the use of Xarelto for the treatment of coronary or peripheral artery disease, Weinstein tells investors in a research note. His statistical analysis suggests a minimum 25% reduction in major adverse cardiac events, or MACE. This would make COMPASS a "landmark event in the treatment of CAD/PAD" and lead to Xarelto being adopted as the new standard of care in this greater than $5B indication, Weinstein writes. He recommends buying J&J shares ahead of the European Society of Cardiology meeting and keeps an Overweight rating on the name.
08/31/17
UBSW
08/31/17
NO CHANGE
Target $148
UBSW
Buy
Johnson & Johnson remain a top pick, says UBS
UBS analyst Matt Miksic met with Johnson & Johnson management and came away remaining confident in his conviction of his bullish view on the company. The analyst sees sustained Pharma growth, stable Med Device growth and an improving Consumer division. He identifies multiple drivers, including its pipeline and potential deal interest in Eye Care, Dental, Structural Heart and Neurology. Miksic reiterated his Buy rating and $148 price target on the stock, adding Johnson & Johnson remains a top pick.
LLY Eli Lilly
$82.44

-0.63 (-0.76%)

08/31/17
LEER
08/31/17
NO CHANGE
LEER
Market Perform
Leerink remains cautious on Eli Lilly, Incyte baricitinib outlook
Leerink analyst Seamus Fernandez notes that Eli Lilly (LLY) and Incyte (INCY) announced that the New Drug Application for baricitinib will be resubmitted by the end of January 2018, following recent discussions with the FDA. Though the news comes as a positive surprise, the analyst remains cautious on his baricitinib outlook as it isstill unclear whether or not the new data will satisfy concerns raised by U.S. regulators in the April complete response letter citing dosing and safety issues. He reiterates a Market Perform rating on Eli Lilly's shares.
09/15/17
JEFF
09/15/17
NO CHANGE
Target $96
JEFF
Buy
Eli Lilly price target raised to $96 from $89 at Jefferies
Jefferies analyst Jeffrey Holford raised his price target for Eli Lilly to $96 citing confidence in management's ability to deliver on margin commitments. Investors should not underappreciate Lilly's visibility on mid-single digit revenue growth paired with "significant operating leverage off a low margin base," Holford tells investors in a research note. He reiterates a Buy rating on the shares.
09/13/17
RHCO
09/13/17
NO CHANGE
RHCO
Eli Lilly Jardiance data positive, says SunTrust
SunTrust analyst John Boris says that data on the efficacy of Eli Lilly's Jardiance drug showed that it " reduces risk of cardiovascular death in type 2 diabetes patients irrespective of background blood glucose levels." The analyst thinks the data supports the use of the drug "in various (type 2 diabetes) settings." He expects the company's diabetes business to reach $10.5B in 2021, up from $4.4B in 2013. Boris keeps a $96 price target and a Buy rating on the shares.
09/15/17
MSCO
09/15/17
NO CHANGE
Target $86
MSCO
Equal Weight
Morgan Stanley says baricitinib efficacy could be better if trial design changed
Morgan Stanley analyst David Risinger said Eli Lilly (LLY) and partner Incyte's (INCY) efficacy data from a Phase 2 study of baricitinib in atopic dermatitis looks inferior to competitors' "on the surface," but he contends that a steroid run-in period and usage during trial makes cross-trial comparison difficult. He thinks better efficacy is likely in Phase 3 if Lilly changes the trial design; however, if it does not, it could "end up being a commercial liability," Risinger tells investors. He keeps an Equal Weight rating and $86 price target on Eli Lilly shares.
LMNS Lumenis

NVS Novartis
$85.58

-0.25 (-0.29%)

08/31/17
MSCO
08/31/17
NO CHANGE
MSCO
Equal Weight
Gilead response to Kymriah pricing 'confusing,' says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said Novartis' (NVS) pricing of its Kymriah therapy at $475,000 gross puts "some slight pressure" on his model for Juno Therapeutics (JUNO), though he doesn't see it as "that far out of line" with his expectations. While he said it makes sense that Juno saw some pressure yesterday after the pricing news and that bluebird bio (BLUE) closed the gap with Juno, he called Gilead's (GILD) strength yesterday "a bit more confounding" given that Gilead is focused on the same indication as Juno. However, initial DLBCL sales in 2018 for both Gilead and Novartis are likely to drive sentiment, so greater clarity won't be seen until then, added Harrison, who keeps an Equal Weight rating on Juno shares.
08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
08/29/17
CANT
08/29/17
NO CHANGE
Target $10
CANT
Overweight
Cantor positive on Amarin after Novartis study results
Cantor Fitzgerald analyst Louise Chen believes the Phase 3 CANTOS study results from Novartis (NVS) support the hypothesis that a long-term drug treatment focused on an anti-inflammatory mechanism in patients with a prior heart attack and inflammatory atherosclerosis can reduce cardiovascular events. In two Phase 3 trials, Amarin's (AMRN) Vascepa affected inflammatory markers including hsCRP and Lp-PLA2 while also improving lipid biomarkers, Chen tells investors in a research note. CANTOS and other recently reported studies help to increase her confidence in a positive and commercial outcome for Amarin's REDUCE-IT trial. The analyst has an Overweight rating on the shares with a $10 price target.
07/26/17
07/26/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Hold from Underperform at Jefferies with analyst Andy Barish saying the current valuation and consensus estimates "now reflect the reality" of Chipotle's path to recovery. 2. Biogen (BIIB) upgraded to Buy from Neutral at Goldman Sachs with analyst Terence Flynn saying the company's balance sheet is under-levered, which provides flexibility, while Aducanumab provides Alzheimer's optionality. 3. DSW (DSW) upgraded to Outperform from Neutral at Wedbush with the firm saying it is more confident that second quarter results will beat expectations and that the company will reiterate its full-year guidance after conducting checks and speaking with the company. 4. Electronic Arts (EA) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post citing a strong fiscal 2019 outlook. 5. Novartis (NVS) upgraded to Overweight from Underweight at Morgan Stanley with analyst Vincent Meunier upgrading the company two notches to Overweight from Underweight following a "massive" reset in consensus expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer
$35.36

-0.37 (-1.04%)

08/23/17
RAJA
08/23/17
NO CHANGE
Target $36
RAJA
Strong Buy
Paratek takeover speculation 'seems plausible,' says Raymond James
After Bloomberg reported that Paratek Pharmaceuticals (PRTK) is exploring its strategic options, including a possible sale, after receiving takeover interest, Raymond James analyst Laura Chico said she sees omadacycline as a promising asset and sees a takeout as "certainly one plausible outcome." While its "probably premature to think about a takeout price," Chico said that a possible price could arguably fall in the high-$40 to low-$50 range, adding that Merck (MRK), Pfizer (PFE) and Allergan (AGN) would all be potential buyers. She keeps a Strong Buy rating and $36 price target on Paratek shares.
08/30/17
JEFF
08/30/17
NO CHANGE
Target $89
JEFF
Buy
Eli Lilly can rally 5% on September data, says Jefferies
Jefferies analyst Jeffrey Holford sees upside of 3%-5% for Eli Lilly (LLY) shares if the MONARCH 3 data at ESMO on September 10 shows a differentiated efficacy profile. The analyst sees downside of 2%-4% if abemaciclib's hazard ratio is inferior to Pfizer's (PFE) Ibrance. Holford believes expectations are modest for abemaciclib and that shares of Lilly remain attractive over the mid-term. He has a Buy rating on the name with an $89 price target.
09/11/17
CANT
09/11/17
NO CHANGE
Target $32
CANT
Neutral
Epipen market likely unaffected by Pfizer warning letter, says Cantor
Cantor Fitzgerald analyst Louise Chen said Friday that she does not expect the FDA's warning letter to Pfizer (PFE) to result in any material change in the market for Mylan's (MYL) Epipen in the near term. In a research note titled "No Need To Go Into Shock Yet Over PFE Warning Letter For Epipen," Chen added that she thinks Pfizer will work with the FDA to get the warning letter resolved. This news could be positive for Impax Laboratories (IPXL), which has the capacity to supply 30% of the market, above its current mid-20% range market share, Chen contends. She has a Neutral rating on Mylan and Overweight rating on Impax.
SNY Sanofi
$48.43

-0.29 (-0.60%)

08/30/17
08/30/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Sanofi (SNY) upgraded to Hold from Reduce at HSBC, with analyst Steve McGarry citing valuation. 2. M.D.C. Holdings (MDC) upgraded to Market Perform from Underperform at Wells Fargo with analyst Stephen East saying he sees "little reason the equity would move meaningfully lower" from current levels. 3. Ciena (CIEN) upgraded to Buy from Neutral at Citi with analyst Stanley Kovler saying the risk/reward is positive into third quarter results. 4. Six Flags (SIX) upgraded to Buy from Neutral at Hilliard Lyons with analyst Jeff Thomison citing improved valuation based on its 13% year-to-date pullback. 5. Prospect Capital (PSEC) upgraded to Market Perform from Underperform at Raymond James with analyst Robert Dodd saying he expects near-term earnings will cover the lower dividend run-rate but notes downside risk remains. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/17
FBCO
09/11/17
NO CHANGE
Target $485
FBCO
Outperform
Regeneron, Sanofi asthma trial 'statistically significant,' says Credit Suisse
Credit Suisse analyst Alethia Young notes that Regeneron (REGN)/Sanofi (SNY) released top-line asthma results, and the overall trial was "statistically significant." Specifically, the trial hit in the overall population, but it is unclear if the trial was statistically significant in the low eosinophil level patients alone, she notes. The analyst reiterates an Outperform rating and $485 price target on Regeneron's shares.
08/30/17
HSBC
08/30/17
UPGRADE
Target $81
HSBC
Hold
Sanofi upgraded to Hold from Reduce at HSBC
HSBC analyst Steve McGarry upgraded Sanofi to Hold and increased its price target to $81 from $79 citing valuation and said he sees few catalysts to own the shares either.
07/31/17
ADAM
07/31/17
NO CHANGE
Target $522
ADAM
Buy
Dupixent authorization approval rate outweighs Q2 miss, says Canaccord
Regeneron (REGN) partner Sanofi (SNY) reported a "very high" 73%-83% prior authorization approval rate for Dupixent in Q2, which Canaccord analyst John Newman said outweighs the fact that sales for the drug at $30.6M were slightly below the $33M consensus forecast. The analyst, who sees rapid payor acceptance of Dupixent as "much more crucial" than the initial quarterly revenue, keeps a Buy rating and $522 price target on Regeneron shares.
REGN Regeneron
$433.45

-7.81 (-1.77%)

09/14/17
RBCM
09/14/17
INITIATION
Target $475
RBCM
Sector Perform
Regeneron initiated with a Sector Perform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Regeneron with a Sector Perform and a $475 price target.
09/07/17
PIPR
09/07/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron selloff today a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes shares of Regeneron Pharmaceuticals (REGN) are trading lower after Phase IIb readouts from competitors Amgen (AMGN) and AstraZeneca (AZN) in asthma and AbbVie (ABBV) in atopic dermatitis met their primary endpoints. The analyst does not see an "immediate competitive threat" to Regeneron's Dupixent, which he says has successfully launched in atopic dermatitis following FDA approval in March. He recommends buying the shares on today's selloff ahead of expected "positive" Phase III Dupixent asthma data. Dupixent maintains at least a two-year lead ahead of these competitive agents, Tenthoff tells investors in an intraday research note. The analyst reiterates an Overweight rating on Regeneron with a $557 price target.
09/11/17
PIPR
09/11/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron pullback today a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends using today's weakness in shares of Regeneron Pharmaceuticals as a buying opportunity. The analyst calls the Phase III Quest data in severe asthma patients positive and projects peak U.S. asthma sales of $2.2B by 2025. He reiterates an Overweight rating on Regeneron with a $557 price target. The stock in early trading is down 6% to $443.39.

TODAY'S FREE FLY STORIES

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.